Please login to the form below

Not currently logged in
Email:
Password:

MS symptom drug approved in US

The US FDA has approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis

The US Food and Drug Administration (FDA) has approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). Ampyra is the first therapy to be approved for this use.

The drug will be manufactured by Irish pharmaceutical company, Elan, and will be distributed in the US by Acorda Therapeutics.

Shane Cooke, executive vice president and head of Elan Drug Technologies said: "We wish to congratulate Acorda Therapeutics on the approval of Ampyra, which will bring a very important and much needed therapy to the market for MS sufferers."

Data from clinical trials shows that patients treated with Ampyra had faster walking speeds than those receiving a placebo. MS is a chronic disease affecting the central nervous system, often with disability affects. It is estimated to affect around 400,000 people in the US and 2.5 million people worldwide.

When given in doses higher than the recommended 10mg twice daily, Ampyra can cause seizures. Other reported side effects include insomnia, nausea, weakness and balance disorder.

25th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics